Skip to main content
Dennis Bourdette, MD, Neurology, Portland, OR

DennisNeilBourdetteMDFAAN, FANA

Neurology Portland, OR

Neuroimmunology/Multiple Sclerosis

Former Chair and Professor Emeritus Department of Neurology Oregon Health & Science Unitvrrsity

Dr. Bourdette is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Bourdette's full profile

Already have an account?

  • Office

    3181 SW Sam Jackson Park Rd
    Portland, OR 97239
    Phone+1 503-494-7321

Education & Training

  • Oregon Health & Science University (OHSU Health)
    Oregon Health & Science University (OHSU Health)Residency, Neurology, 1979 - 1982
  • Santa Clara Valley Medical Center
    Santa Clara Valley Medical CenterInternship, Internal Medicine, 1978 - 1979
  • University of California, Davis, School of Medicine
    University of California, Davis, School of MedicineClass of 1978

Certifications & Licensure

  • OR State Medical License
    OR State Medical License 1980 - 2025
  • MP State Medical License
    MP State Medical License 2017 - 2019
  • American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Hypothalamic-Pituitary-Thyroid Axis Perturbations in Male Mice by CNS-Penetrating Thyromimetics  
    Dennis Bourdette, MD, Endocrinology

Press Mentions

  • Newly Discovered Compound Could Repair Myelin Fibres and Prevent the Progression of Neurodegenerative Diseases
    Newly Discovered Compound Could Repair Myelin Fibres and Prevent the Progression of Neurodegenerative DiseasesMarch 18th, 2022
  • Guillain-Barre Risk up Slightly After Shingrix
    Guillain-Barre Risk up Slightly After ShingrixNovember 1st, 2021
  • Guillain-Barré Case Reported After Covid-19 Vaccination
    Guillain-Barré Case Reported After Covid-19 VaccinationApril 9th, 2021
  • Join now to see all

Grant Support

  • Small Molecules Targeting The Mitochondrial Permeability TransitionNational Institute On Drug Abuse2012
  • Lipoic Acid Therapy For Experimental Autoimmune EncephalomyelitisVeterans Affairs2011–2012
  • Mitochondrial Modulation For Neuroprotection In A Model Of Multiple SclerosisNational Institute Of Neurological Disorders And Stroke2008–2012
  • Jungers Center New Faculty Recruitment In Genetic Models Of Axonal DegenerationNational Institute Of Neurological Disorders And Stroke2009–2010
  • Study To Evaluate The Role Of An Oral Antioxidant, Alpha Lipoic Acid In MSNational Center For Research Resources2004
  • Natural Antioxidant In The Treatment Of MSNational Center For Complementary &Alternative Medicine1999

Professional Memberships